Susan Hodge
Physician Assistant · Barbourville, KYNPI 1942305156
Payments from drug & device makers
Across 218 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$496
- AbbVie$430
- AstraZeneca$388
- Ironwood Pharmaceuticals, Inc$313
- Novo Nordisk$307
- Biohaven Pharmaceuticals, Inc.$236
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,703100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 30 | $496 |
| AbbVie | 29 | $430 |
| AstraZeneca | 13 | $388 |
| Ironwood Pharmaceuticals, Inc | 23 | $313 |
| Novo Nordisk | 23 | $307 |
| Biohaven Pharmaceuticals, Inc. | 12 | $236 |
| Bayer | 10 | $187 |
| Lilly USA, LLC | 12 | $187 |
| Novartis | 9 | $186 |
| Astellas Pharma US Inc | 8 | $118 |
| Merck | 7 | $111 |
| Axsome Therapeutics, Inc. | 4 | $76 |
| Sanofi-aventis U.S. LLC | 5 | $74 |
| GSK | 4 | $74 |
| Amarin Pharma, Inc. | 5 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| BETA Bionics, Inc. | 2 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| Insulet Corporation | 1 | $42 |
| Dexcom, Inc. | 2 | $40 |
| Amgen | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Boehringer Ingelheim | 2 | $25 |
| Johnson & Johnson | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$218
- NURTEC ODT$102
How this compares
$3,703 in reported general payments places this provider in the 85th percentile of 1,448 physician assistant providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 101 | $116,332 |
| OzempicSemaglutide | 85 | $94,371 |
| EliquisApixaban | 90 | $80,020 |
| VraylarCariprazine Hcl | 41 | $63,784 |
| JardianceEmpagliflozin | 58 | $47,333 |
| FarxigaDapagliflozin Propanediol | 46 | $43,020 |
| MyrbetriqMirabegron | 32 | $27,750 |
| XareltoRivaroxaban | 37 | $25,194 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $22,947 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $20,905 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $17,046 |
| LinzessLinaclotide | 27 | $16,490 |
| JanuviaSitagliptin Phosphate | 16 | $13,818 |
| Bydureon BciseExenatide Microspheres | 17 | $13,602 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $11,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $187 | $116,332101 claims |
| Novo NordiskOzempic | $307 | $94,37185 claims |
| AbbVieVraylar, Linzess | $430 | $80,27468 claims |
| PfizerEliquis | $496 | $80,02090 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $388 | $55,22870 claims |
| Boehringer IngelheimJardiance | $25 | $47,33358 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $74 | $39,99362 claims |
| Astellas Pharma US IncMyrbetriq | $118 | $27,75032 claims |
| MerckJanuvia, Janumet | $111 | $25,73437 claims |
| Johnson & JohnsonXarelto | $24 | $25,19437 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $74 | $10,29020 claims |
| NovartisEntresto | $186 | $9,44414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,448 physician assistant providers in Kentucky.
Other physician assistant in Barbourville
- Brandice HarrisonLexington$745K
- Lauren MeadeLexington$656K
- Melissa DavisLouisville$362K
- Kara MuddLouisville$98K
- Seth KingBowling Green$91K
- Marty MullinsHazard$63K
- Lauri GarnerVersailles$33K
- Robert TatumLouisville$29K
- Michelle JonesLexington$29K
- Grace IsaacsLouisville$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.